TG Therapeutics, Inc. (BIT:1TGTX)

-0.79% (1Y)

Market Cap	5.13B
Revenue (ttm)	357.48M
Net Income (ttm)	36.22M
Shares Out	n/a
EPS (ttm)	0.22
PE Ratio	141.61
Forward PE	28.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	33.30
Day's Range	n/a
52-Week Range	29.65 - 40.00
Beta	n/a
RSI	59.35
Earnings Date	Aug 4, 2025

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 338
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1TGTX

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD